194 related articles for article (PubMed ID: 29366663)
1. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
Takeuchi M; Doi T; Obayashi K; Hirai A; Yoneda K; Tanaka F; Iwai Y
Immunol Lett; 2018 Apr; 196():155-160. PubMed ID: 29366663
[TBL] [Abstract][Full Text] [Related]
2. Soluble PD-L1 predicts tumor response and immune-related adverse events in patients with advanced melanoma treated with anti-PD-1 antibodies.
Oya K; Nakamura Y; Shen LT; Ishizuki S; Matsusaka S; Fujisawa Y
J Dermatol; 2024 Jun; 51(6):807-815. PubMed ID: 38433350
[TBL] [Abstract][Full Text] [Related]
3. Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients.
Kashiwada T; Takano R; Ando F; Kuroda S; Miyabe Y; Owada R; Miyanaga A; Asatsuma-Okumura T; Hashiguchi M; Kanazawa Y; Yoshida H; Seike M; Gemma A; Iwai Y
Front Pharmacol; 2024; 15():1384733. PubMed ID: 38799168
[No Abstract] [Full Text] [Related]
4. Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy.
Dong C; Hui K; Gu J; Wang M; Hu C; Jiang X
Anticancer Drugs; 2024 Jun; 35(5):418-425. PubMed ID: 38386011
[TBL] [Abstract][Full Text] [Related]
5. The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.
Kurosaki T; Chamoto K; Suzuki S; Kanemura H; Mitani S; Tanaka K; Kawakami H; Kishimoto Y; Haku Y; Ito K; Sato T; Suminaka C; Yamaki M; Chiba Y; Yaguchi T; Omori K; Kobayashi T; Nakagawa K; Honjo T; Hayashi H
Front Immunol; 2023; 14():1325462. PubMed ID: 38149256
[TBL] [Abstract][Full Text] [Related]
6. Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy - A CEPAC-TDM biomarker substudy.
Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
Tumour Biol; 2024; 46(s1):S355-S367. PubMed ID: 38277316
[TBL] [Abstract][Full Text] [Related]
7. Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.
Chivu-Economescu M; Herlea V; Dima S; Sorop A; Pechianu C; Procop A; Kitahara S; Necula L; Matei L; Dragu D; Neagu AI; Bleotu C; Diaconu CC; Popescu I; Duda DG
Gastric Cancer; 2023 Nov; 26(6):934-946. PubMed ID: 37668884
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint activity exacerbate renal interstitial fibrosis progression by enhancing PD-L1 expression in renal tubular epithelial cells.
Zhang Y; Mi X; Zhang Y; Li J; Qin Y; He P; Zhao Y; Su B; He L
Transl Res; 2024 Sep; 271():52-67. PubMed ID: 38723861
[TBL] [Abstract][Full Text] [Related]
9. Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases.
Bailly C; Thuru X; Quesnel B
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34204509
[TBL] [Abstract][Full Text] [Related]
10. Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.
Ando F; Kashiwada T; Kuroda S; Fujii T; Takano R; Miyabe Y; Kunugi S; Sakatani T; Miyanaga A; Asatsuma-Okumura T; Hashiguchi M; Kanazawa Y; Ohashi R; Yoshida H; Seike M; Gemma A; Iwai Y
Front Pharmacol; 2024; 15():1384731. PubMed ID: 38774209
[TBL] [Abstract][Full Text] [Related]
11. sPD-L1 and sPD-L2 in plasma of patients with lung cancer and their clinical significance.
Han S; Zhang Y; Yuan J; Wu Y; Zhou Y; Zhou Y; Li X; Zhou S
Cytokine; 2024 Apr; 176():156532. PubMed ID: 38330638
[TBL] [Abstract][Full Text] [Related]
12. Soluble PD-L1 reprograms blood monocytes to prevent cerebral edema and facilitate recovery after ischemic stroke.
Kim JE; Lee RP; Yazigi E; Atta L; Feghali J; Pant A; Jain A; Levitan I; Kim E; Patel K; Kannapadi N; Shah P; Bibic A; Hou Z; Caplan JM; Gonzalez LF; Huang J; Xu R; Fan J; Tyler B; Brem H; Boussiotis VA; Jantzie L; Robinson S; Koehler RC; Lim M; Tamargo RJ; Jackson CM
Brain Behav Immun; 2024 Feb; 116():160-174. PubMed ID: 38070624
[TBL] [Abstract][Full Text] [Related]
13. Role of sPD-1 and sPD-Ls in the pathogenesis of connective tissue disease.
He H; He X; Zhou M; Tang Y; Dai L; Xie Z; Wang Y; Xie C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):444-454. PubMed ID: 37164928
[TBL] [Abstract][Full Text] [Related]
14. Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist.
Ng KW; Attig J; Young GR; Ottina E; Papamichos SI; Kotsianidis I; Kassiotis G
Elife; 2019 Nov; 8():. PubMed ID: 31729316
[TBL] [Abstract][Full Text] [Related]
15. Development of a microcantilever-based biosensor for detecting Programmed Death Ligand 1.
Neairat T; Al-Gawati M; Tul Ain Q; Assaifan AK; Alshamsan A; Alarifi A; Alodhayb AN; Alzahrani KE; Albrithen H
Saudi Pharm J; 2024 Jun; 32(6):102051. PubMed ID: 38812944
[TBL] [Abstract][Full Text] [Related]
16. Novel ultrasensitive automated kinetic exclusion assay for measurement of plasma levels of soluble PD-L1, the predictive and prognostic biomarker in cancer patients treated with immune checkpoint inhibitors.
Darwish IA; Alahmad W; Vinoth R
Heliyon; 2024 May; 10(10):e31317. PubMed ID: 38803937
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of ELISA method for quantification of Q-1802 in serum and its application to pharmacokinetic study in ICR Mouse.
Meng Q; Hao Y; Yang M; Du Y; Wang S
J Pharm Biomed Anal; 2024 Aug; 245():116138. PubMed ID: 38636191
[TBL] [Abstract][Full Text] [Related]
18. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
[No Abstract] [Full Text] [Related]
19. Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer.
Kato Y; Kashima J; Watanabe K; Yomota M; Zenke Y; Okuma Y; Hosomi Y; Gemma A; Seike M; Okamura T
Anticancer Res; 2018 Feb; 38(2):1077-1083. PubMed ID: 29374744
[TBL] [Abstract][Full Text] [Related]
20. Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer.
Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
Oncotarget; 2017 Dec; 8(69):113807-113816. PubMed ID: 29371947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
